Background: Conventional methods used to identify BRCA1 and BRCA2 germline mutations in hereditary cancers, such as Sanger sequencing/MLPA, are time-consuming and expensive, due to the large size of the genes. The recent introduction of Next-Generation Sequencing benchtop platforms offered a powerful alternative for mutation detection, dramatically improving the speed and the efficiency of DNA testing. Here we tested the performance of the Ion Torrent PGM platform with the Ion AmpliSeq BRCA1 and BRCA2 Panel in our clinical routine of breast/ovarian hereditary cancer syndrome assessment.
216 BRCA1 and BRCA2 genomic rearrangements were searched by the Multiple-Ligation-dependent-217 Probe-Amplification (MLPA) methodology (Schouten et al., 2002) according to the manufacturer's 218 instructions (MRC-Holland, Amsterdam, The Netherlands) and as described (Buffone et al., 2007; 219 Coppa et al., 2018) Variations in peak height were evaluated comparing each sample with a normal 220 control and by a cumulative comparison.
222 RESULTS
223 Coverage data analysis 224 The BRCA1 and BRCA2 panel used in this study generates 167 amplicons that cover all targeted 225 coding exons and exon-intron boundaries. The data coverage in 147 patients (TS and VS) 226 showed a mean amplicon reading depth per sample ranging from 244x to 2236x, loading 2/4 227 samples on chips 314v2 or 8 samples on chip 316v2. An adequate number of reads mapped onto 228 target regions has been obtained both with chip314v2 or chip316v2, with a mean sequencing 229 depth and an average uniformity of coverage of 726× and 97% and 1504x and 97%, respectively 230 ( Table 2, Table S2 and Table S3 ). The large increase in sequencing efficiency observed with the 231 316v2 chips makes the analysis of a better quality and led to a lower number of false-positive 232 indel calls. For variant calls, we chose the threshold of a minimum average depth of 100x, 233 although a minimum average of 80x is normally required for germline mutations (Trujillano et 234 al., 2015) and a minimum average depth in strand bias of 30x for each strand end to end. By a 235 critical analysis of the BRCA1 and BRCA2 coverage data performed on 147 samples (TS and VS) 236 emerged that some amplicons (herein defined as lower-performance amplicons) often did not 237 reach a minimum coverage of 100x or showed fwd/rev end to end unbalance (Table 3 and Fig. 238 1). In particular, the coverage of the AMPL225438570 BRCA1 amplicon was <100x in 61% of 239 samples (Fig. 1A ). This amplicon maps in the exon 2 of the BRCA1 gene, containing a large A-T 240 reach region, likely to be responsible for lower amplification efficiency. Concerning BRCA2, we 241 observed five amplicons with a coverage less than 100x, whose GC content, self-242 annealing/hairpin formation and GC clamp issues could be responsible for low performance 243 (Table 3 and Fig. 1B ). The same issues may also be responsible for fwd/rev end to end unbalance 244 observed in the following amplicons: AMPL223735053, AMPL223413081, AMPL223712774 in 245 BRCA1 (Fig. 1C, Fig. 1D and Table 3) ; AMPL224626553, AMPL223938117, 246 AMPL223512592, AMPL225349438, AMPL223730984, AMPL223515418, AMPL225441321, 278 (Table 4) . Therefore, considering LGRs as FNs, the concordance with Sanger sequencing 279 analysis was 100%. 280 All these data indicated that an appropriate setting of the analytical pipeline can affect the 281 accuracy of a variant call.
282 This optimized pipeline was then blindly applied on the VS of 136 samples, whose genotype was 283 unknown. We detected pathogenic variants in 30 (22%) cases, 20 in BRCA1 (15%), 10 in BRCA2 284 (7%), 1 BRCA1 VUS, and 1 BRCA2 VUS. All variants were confirmed by Sanger sequencing in 285 their correct zygosity status ( Table 5 ). The remain 104 samples, negative for pathogenic variants, 286 subjected to MLPA analysis were also negative for the presence of LGRs. Of note, one of the 287 BRCA2 deleterious mutations (c.72delA) was a novel disease causing variant at exon 3, predicted 288 to code for an early truncated protein (p.Gly25Aspfs), thus falling into class V (Plon et al., 2008;  289 ENIGMA consortium: https://enigmaconsortium.org/library/general-documents/enigma-290 classification-criteria/). The novel mutation has been identified in one HBC family having a 291 clear dominant inheritance pattern and with three cases of breast cancer before 40 years age 292 ( Figure S2 ). It has not yet been possible to perform segregation analysis in this family. 293 A complete BRCA1 and BRCA2 Sanger sequencing has been performed in 60 negative samples 294 of VS (included in the 104 negative samples), because their higher expectation to be carrier of 295 pathogenic mutations. As expected, Sanger sequencing not only confirmed the absence of 296 BRCA1 and BRCA2 pathogenic variants, but also identified all benign variants in their correct 297 zygosity status as detected by NGS (Table S4 ). The variants located in regions not covered by 298 the respective primers have been excluded from this evaluation. Altogether, our data strongly 299 suggest that Ion Torrent PGM and Ion AmpliSeq BRCA1 and BRCA2 Panel (Life Technologies) 300 represent an excellent system to be applied in the field of diagnostics with 100% of concordance 301 and sensitivity compared to Sanger method.
302 Our study enabled us to generate a standardized diagnostic workflow useful in clinical practice to 303 quickly screen the BRCA1 and BRCA2 genes (Fig. 4) . Michils et al., 2012; Chan et al. 2012; Feliubadalo et al., 2013) .
322
Recently, different platforms have been validated showing a comparable quality of data 323 and throughput capacity (Voelkerding et al., 2009; Rothberg et al., 2011; Loman et al., 2012; 324 Wallace et al., 2016) . In this study, we validated the Ion Torrent PGM platform in combination 325 with the ready-to-use Ion AmpliSeq BRCA1 and BRCA2 Panel (Life Technologies), as, in our 326 opinion, it may be a good candidate for clinical BRCA1 and BRCA2 sequencing. BRCA genes are 327 also involved in the development of sporadic breast and ovarian tumors; and patients, carrying a 328 germline or somatic BRCA1/BRCA2 variants, may benefit from PARP inhibitors therapy 329 (Coleman, et al., 2017; Robson et al., 2017; Oza et al.,2018; Litton et al., 2018) . Investigating 330 BRCA1 and BRCA2 mutation status in ovarian and breast cancer tissues patients, has a key role 331 in addressing the therapeutic choices. Several studies demonstrated that NGS could be an 332 efficient method for detecting somatic mutations in BRCA1 and BRCA2 genes using DNA from 333 formalin-fixed and paraffin-embedded (FFPE) breast and ovarian cancer tissues (Ellison G et al 334 2015; Mafficini et al 2016; Enyedi et al., 2016) . In our laboratory the Ion Torrent PGM platform 335 is currently used for the routine molecular characterization of FFPE tumor tissues from colon or 336 lung cancers patients (Belardinilli et al., 2015) with a highly satisfactory performance.
337
The accuracy of NGS approach represents an important requirement in diagnostic 338 applications, and it strongly depends on the read depth and on the analytical pipeline (Goldfeder 339 et al., 2016) . In our tests, we achieved an acceptable sequencing depth and average uniformity of 340 amplicons coverage in all samples. 60 of the104 BRCA1 and BRCA2 negative samples, that 341 showed a higher expectation to be carrier of pathogenic mutations (i.e. HBC with BRCAPro5.1 342 greater than 40%, Male Breast Cancer or HBOC cases), were also subjected to BRCA1 and 343 BRCA2 Sanger sequencing. We observed 100% sensitivity and 100% concordance as well as 344 correct estimate heterozygote and homozygote status.
345
A limit of Ion AmpliSeq BRCA1 and BRCA2 Panel (Life Technologies) is represented 346 by the small group of lower-performance amplicons, that either did not reach a minimum 347 coverage of 100x, as also reported by Pilato et al. (Pilato et al., 2016) , or showed fwd/rev end to 348 end unbalance. The mean amplicon read depth could be affected by the large A-T reach region or 349 GC content, self-annealing/hairpin formation and/or GC clamp issues (Yan et al., 2016) . We 350 overcame these limits performing, in all samples, Sanger sequencing for the regions covered by 351 low performance amplicons. In addition, the presence of highly homopolymeric regions in the 352 BRCA1 and BRCA2 genes and the nature of semiconductor sequencing chemistry of Ion Torrent 353 PGM were shown to limit the correct call of indel variants in these regions (Yeo et al., 2014; 354 Zanella et al., 2017) . Nonetheless, we did not observe incorrect calls in these regions in our 355 samples.
356
A complete clinical level analysis of BRCA1 and BRCA2 includes the study of LGRs. In 357 our experience, the Ion AmpliSeq BRCA1 and BRCA2 Panel (Life Technologies) was not 358 feasible for analyzing copy number alteration due to the sequencing read length (range, 71-239 359 bp) and to the high number of false positive obtained (Pilato et al., 2016) . Therefore, the MLPA 360 analysis is always required using this panel. More recently, Thermo Fisher Scientific's developed 361 Oncomine ® BRCA Research Panel, that seems to solve all these issues (Hirotsu et al., 2017) .
362
Noteworthy, we identified also a novel disease-causing mutation at exon 3 of BRCA2 (Feliubadalo et al., 2013; Yeo et 370 al., 2014; Trujillano et al., 2015) , shows that NGS performed with a commercial panel (Ion 
